We advised Mabwell on its IPO and HKEX listing

Davis Polk advised Mabwell (Shanghai) Bioscience Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and its international offering pursuant to Regulation S. The net proceeds of the offering were approximately HK$1.2 billion.

Mabwell is a pharmaceutical company in China recognized for its ability to innovate in drug development and for its end-to-end capabilities from drug discovery to commercial sales.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu, counsel - registered foreign lawyer Jennifer (Yujia) Jiang and counsel Wendy Kan and associates Sarah Shi and Andrew Pu. Counsel Alon Gurfinkel and associate Kelli A. Rivers provided tax advice. Members of the Davis Polk team are based in the Hong Kong, Beijing and London offices.

Copy link to share post